The experts at Excore Consulting have a longstanding experience of both in-/out- licensing of drug development programs, as well as M&A’s, and they have established valuable contacts and relationships with most of “big pharma”. Excore Consulting’s business model is to engage themselves early in the preparations of a future partnering; up to three years before a planned exit. In the preparation of a planned exit (sale, IPO, out-licensing), the company provides suggestions and challenges to important decisions and executions in order to improve/increase the value of the asset or project, as well as engaging themselves in the closing of the transaction (negotiations, financial/ legal/contractual support).
- Bli medlem
- Om SwedenBIO